Targeted Diagnostics Heligenics provides functional mutation data via the GigaAssay to improve genetic test interpretation for cancer diagnostics companies, presenting a clear entry point for sales conversations with diagnostic firms seeking enhanced variant interpretation and precision medicine approaches.

Precision Medicine Enablement The ability to convert generic drugs into targeted precision medicines and to rescue failed drug candidates through genetically stratified clinical trials offers a compelling value proposition for pharmaceutical companies striving to improve trial success rates and drug lifecycle management.

High Impact Differentiator High Content Screening for Biologic Drugs positions Heligenics as a unique provider in biotech, enabling faster functional assessment of mutations in proteins, which can be marketed to partners looking to de-risk biologics development and accelerate research timelines.

Growth Momentum Recent financing of 4.5M and a revenue range of 1M to 10M indicate early-stage traction with potential for scalable partnerships; sales efforts can emphasize growth potential, funding readiness, and opportunity for co-development deals with larger biotech players.

Collaborative Partnerships With a small team (11-50 employees) and a clear focus on genetics-to-health outcomes, Heligenics is an attractive partner for CROs, academic collaborations, and biotech startups seeking flexible, fast-moving research collaborations and co-innovation opportunities.